

Product Name: Cyclosporine oral solution
Issued: Jun-13-2013

SAFETY DATA SHEET

Section 1. Identification of the substance/mixture and of the company/undertaking

1.1 Product Identifier

Product Name: Cyclosporine oral solution
Synonyms: Gengraf Oral Solution, 100 mg/mL: Gengraf Oral Solution
Trade name: Gengraf
List Number: 7269

1.2 Relevant identified uses of the substance or mixture and uses advised against

Recommended use: Pharmaceuticals

1.3 Details of the supplier of the safety data sheet

Supplier: AbbVie Inc.
1 North Waukegan Road
North Chicago, IL 60064
USA
1-800-255-5162
+1-847-937-7433

Customer Service Telephone: 1-800-255-5162 (US and Canada only)
+1-847-937-7433

E-mail Address: AbbVie.SDS@abbvie.com

1.4 Emergency telephone number

Emergency Telephone: CHEMTREC: 1(800) 424-9300 (in USA and Canada)
or +1-703-527-3887 (international)

Section 2. Hazards identification

2.1 Classification of the substance or mixture

Regulation (EC) No 1272/2008

Reproductive toxicity Category 1A
Carcinogenicity Category 1A

Classification according to EU Directives 67/548/EEC or 1999/45/EC

Risk Phrases: R45 - May cause cancer
R60 - May impair fertility
R61 - May cause harm to the unborn child

2.2 Label elements

Product Name: Cyclosporine oral solution
Issued: Jun-13-2013

Section 2. Hazards identification



Signal Word: Danger

Hazard Statements:

H350 - May cause cancer
H360 - May damage fertility or the unborn child

P201 - Obtain special instructions before use
P202 - Do not handle until all safety precautions have been read and understood
P281 - Use personal protective equipment as required
P308 + P313 - IF exposed or concerned: Get medical advice/attention
P405 - Store locked up
P501 - Dispose of contents/container to an approved waste disposal plant

2.3 Other hazards

Not determined

Section 3. Composition/information on ingredients

Chemical Name	Percent	EINECS/ELINCS Number	EEC Classification	EU - GHS Substance Classification	REACH No.
Castor Oil 8001-79-4	30-50	Present		Not Hazardous*	No data available
Propylene Glycol 57-55-6	30-50	Present		Not Hazardous*	No data available
Sorbitan Monooleate 1338-43-8	5-20	Present		Not Hazardous*	No data available
Cyclosporine 59865-13-3	1-9.9	NA	Xn, R22 R45 R60, R61	Acute Tox. 4 (H302) Carc 1B (H350) Repr. 1B (H360)	No data available

Not Hazardous* - Based on available data, not classified as hazardous according to the criteria of the Globally Harmonized System.

For the full text of the R-phrases mentioned in this Section, see Section 16

For the full text of the H-Statements mentioned in this Section, see Section 16

Section 4. First aid measures

4.1 Description of first aid measures

Eye Contact:

Remove from source of exposure. Flush with copious amounts of water. If irritation persists or signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.

Product Name: Cyclosporine oral solution
Issued: Jun-13-2013

Skin Contact: Remove from source of exposure. Flush with copious amounts of water. If irritation persists or signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.

Inhalation: Remove from source of exposure. If signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.

Ingestion: Remove from source of exposure. If signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.

Protection of First-aiders: Use personal protective equipment

4.2 Most important symptoms and effects, both acute and delayed

Signs and Symptoms: Clinical data suggests the following: abnormal kidney function, tremor, hirsutism (abnormal hairiness), gastrointestinal upset, rash, increased blood pressure, abnormal liver function, excessive urination. convulsion, alterations in blood chemistry.

Medical Conditions Aggravated by Exposure: Data suggest any pre-existing ailments in the following organs: immune system, kidney, central nervous system, cardiovascular system, eyes, skin, or hematopoietic system. liver. Pregnancy. Hypersensitivity to the material and/or similar materials.

4.3 Indication of any immediate medical attention and special treatment needed

Notes To Physician: Treat symptomatically

Section 5. Firefighting measures

5.1 Extinguishing Media

Suitable Extinguishing Media: Use extinguishing agent suitable for type of surrounding fire

Unsuitable Extinguishing Media: Not determined

5.2 Special hazards arising from the substance or mixture

Special Exposure Hazards: Not determined

5.3 Advice for firefighters

Protective Equipment and Precautions for Firefighters: As in any fire, wear self-contained breathing apparatus and full protective gear

Section 6. Accidental release measures

6.1. Personal precautions, protective equipment and emergency procedures

Personal Precautions: For personal protection see section 8

6.2. Environmental precautions

Environmental Precautions: Contain material and prevent release to waterways or soil.

6.3. Methods and material for containment and cleaning up

Methods for Cleaning Up: Recover product and place in an appropriate container for disposal.

Product Name: Cyclosporine oral solution
Issued: Jun-13-2013

6.4. Reference to other sections

Refer to Sections 8, 12, and 13 for further information.

Section 7. Handling and storage

7.1. Precautions for safe handling

Handle in accordance with good industrial hygiene and safety practice.

7.2. Conditions for safe storage, including any incompatibilities

Store according to label instructions

7.3. Specific end use(s)

Recommended use: Pharmaceuticals

Section 8. Exposure controls/personal protection

8.1. Control parameters

Exposure limits:

Chemical Name	Employee Exposure Limit	Skin Notation
Castor Oil 8001-79-4	Not Applicable	None
Propylene Glycol 57-55-6	Not Applicable	None
Sorbitan Monooleate 1338-43-8	Not Applicable	None
Cyclosporine 59865-13-3	0.2 mg/m ³ TWA	None

Chemical Name	ACGIH TLV	France	German MAK	Ireland	Italy
Propylene Glycol 57-55-6				150 ppm (TWA) 470 mg/m ³ (TWA) 10 mg/m ³ (TWA)	

Chemical Name	The Netherlands	Spain	Switzerland	UK OEL/MEL
Propylene Glycol 57-55-6				450 ppm (STEL) 1422 mg/m ³ (STEL) 30 mg/m ³ (STEL) 150 ppm (TWA) 474 mg/m ³ (TWA) 10 mg/m ³ (TWA)

8.2. Exposure controls

Engineering Controls: No special provisions are required under normal product use conditions. When handling bulk formulation, use in a well-ventilated area.

Respiratory Protection: Respiratory protection is not needed during normal product use. When handling the bulk formulation, an approved respirator (i.e. NIOSH, EN, etc.) should be worn when exposures are expected to exceed the applicable limits.

Product Name:	Cyclosporine oral solution
Issued:	Jun-13-2013
Eyes:	Eye protection not needed during typical product use conditions. Wear eye protection as appropriate when handling the bulk formulation.
Gloves:	Gloves not required during normal product use conditions. Wear impervious gloves when handling the bulk formulation.
Other PPE Data:	Wear appropriate body coverings if contact may occur.
Environmental Exposure Controls:	Not determined

Section 9. Physical and chemical properties

9.1. Information on basic physical and chemical properties

Appearance:	Colorless Mixture Blend Yellow Liquid
Odor:	Not determined.
Odor Threshold:	Not determined
pH:	Not determined.
Boiling Pt. @ 760 mm Hg (°C):	Not determined.
Melting/Freezing Point (°C):	Not determined
Flash Point (°C):	Not determined.
Evaporation Rate at 20°C:	Not determined.
Flammability (Solid):	Not determined.
Lower Explosive Limit:	Not determined.
Upper Explosive Limit:	Not determined.
Vapor Pressure (mm Hg):	Not determined.
Vapor Density (Air = 1):	Not determined.
Specific Gravity:	Not determined.
Solubility(ies):	Not determined.
Partition coefficient: n-octanol/water	Not determined.
Autoignition Temp. (°C):	Not determined.
Decomposition temperature (°C):	Not determined.
Viscosity (centipoise):	Not determined.
Explosion Severity:	Not determined.
Oxidizer Properties:	Not determined.

9.2. Other information

Not determined

Section 10. Stability and reactivity

10.1. Reactivity

Not determined

10.2. Chemical stability

Stable under normal conditions

10.3. Possibility of hazardous reactions

Hazardous reactions: Not determined.

Product Name: Cyclosporine oral solution
Issued: Jun-13-2013

10.4. Conditions to avoid

Not determined.

10.5 Incompatible materials

Not determined

10.6 Hazardous decomposition products

Carbon oxides, Nitrogen oxides (NOx)

Section 11. Toxicological information

11.1. Information on toxicological effects

Routes of Exposure:

Oral: Clinical Route
Dermal: Yes
Inhalation: Unlikely

Acute Toxicity - Oral: Data for component (s) given below.

Chemical Name	Acute Test	Value	Units	Species
Propylene Glycol 57-55-6	LD50 =	10,000-33,700	mg/kg	Animals
Sorbitan Monooleate 1338-43-8	LD50 >	15,000	mg/kg	Rats
Cyclosporine 59865-13-3	LD50 =	1480	mg/kg	Rats
		2329		Mice
	LD50 >	1000		Rabbits
		1000		Hamsters

Acute Toxicity - Dermal: Data for component (s) given below.

Chemical Name	Acute Test	Value	Units	Species
Propylene Glycol 57-55-6	LD50 =	20,800	mg/kg	Rabbits

Acute Toxicity - Inhalation: Not determined.

Other Toxicology Data: Data for component (s) given below:

Chemical Name	Test Type	Value	Units	Species	Comments
Cyclosporine 59865-13-3	LD50 (sc) =	286	mg/kg	Rats	
	LD 50 (iv) >	10-148	mg/kg	Mice	
				Rabbits	
				Rats	

Corrosivity: Not determined.

Dermal Irritation: Not determined.

Eye Irritation: Not determined.

Sensitization: Not determined.

Toxicokinetics/Metabolism: Not determined.

Product Name: Cyclosporine oral solution
Issued: Jun-13-2013

Target Organ Effects: Data for component (s) given below.

Chemical Name	Target Organs:	Species	Dosage	Units	Route	Duration
Cyclosporine 59865-13-3	Kidney	Rats	45	mg/kg	Oral	13 weeks
	Gastrointestinal Tract	Monkeys	60			52 weeks
	Liver	Dogs	45			
	Lymphatic system					
Bone Marrow						
Immune System						

Reproductive Effects: Active Ingredient : In clinical use adverse reproductive effects include: reduced fetal growth. In animals adverse reproductive effects include: testicular atrophy, embryo toxicity,

Data for component (s) given below.

Chemical Name	Species	Dosage	Units	Route	Duration
Cyclosporine 59865-13-3	Rats Rabbits	15	mg/kg	Oral	Premating in Males During Gestation

Carcinogenicity: In clinical use produced tumors in the following tissue (s): lymphatic system. In animals produced tumors in the following tissue (s): lymphatic system, kidney.
Data for component(s) given below.

Chemical Name	Site of Tumors	Species	Dosage	Route	Units	Duration
Cyclosporine 59865-13-3	Lymphatic system Kidney	Mice Rats	7.5	Oral	mg/kg	Lifetime

Mutagenicity: Data for component (s) given below.

Chemical Name	Micronucleus Assay	Ames Test:	Mouse Lymphoma Assay	Chromosomal Abbr. Assay
Cyclosporine 59865-13-3	Negative	Negative	No Data.	Negative

Aspiration hazard: Not determined

Notes:

1. ALD: Approximate lethal dosage
2. LC50: Concentration in air that produces 50% mortality
3. LD50: Oral or dermal dosage that produces 50% mortality

Section 12. Ecological information

12.1. Toxicity

Not determined.

12.2. Persistence and degradability

Not determined.

12.3. Bioaccumulative potential

Not determined

12.4. Mobility in soil

Product Name: Cyclosporine oral solution
Issued: Jun-13-2013

Not determined.

12.5. Results of PBT or vPvB assessment

Chemical safety report is not required for this substance/product.

12.6. Other adverse effects

Do not allow undiluted material or large quantities to reach groundwater, bodies of water or sewer system.

Notes:

- 1. EC50: Concentration in water that produces 50% mortality in Daphnia sp.**
- 2. LC50: Concentration in water that produces 50% mortality in fish.**
- 3. EbC50/ErC50: Concentration in water that produces 50% inhibition of growth and in algae.**

Section 13. Disposal considerations

13.1 Waste treatment methods

Waste Disposal Methods: Disposal should be made in accordance with country, federal, state and local regulations.

Section 14. Transport information

ADR, DOT, ICAO/IATA, IMDG/IMO

Status: Not regulated

- 14.1. UN Number:** Not applicable
14.2. Proper shipping name: Not applicable
14.3. Hazard class: Not applicable
14.4. Packing group: Not applicable
14.5. Environmental hazard: Not applicable
14.6. Special Provisions: Not applicable
14.7. Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code: Not applicable

Section 15. Regulatory Information

15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

International Inventories

Chemical Name	EINECS/ ELINCS	TSCA	DSL	NDSL	PICCS
Castor Oil 8001-79-4	Present	X	X	Not listed.	X
Propylene Glycol 57-55-6	Present	X	X	Not listed.	X
Sorbitan Monooleate 1338-43-8	Present	X	X	Not listed.	X
Cyclosporine 59865-13-3	-	-	X	Not listed.	-

Product Name: Cyclosporine oral solution
Issued: Jun-13-2013

Chemical Name	ENCS	ISHL	IECSC	AICS	KECL	New Zealand
Castor Oil 8001-79-4	Present	-	X	X	Present	
Propylene Glycol 57-55-6	Present	Present	X	X	Present	
Sorbitan Monooleate 1338-43-8	Present	-	X	X	Present	
Cyclosporine 59865-13-3	-	-	X	-	-	

Legend

EINECS/ELINCS - European Inventory of Existing Commercial Chemical Substances/EU List of Notified Chemical Substances
TSCA - United States Toxic Substances Control Act Section 8(b) Inventory
DSL/NDSL - Canadian Domestic Substances List/Non-Domestic Substances List
PICCS - Philippines Inventory of Chemicals and Chemical Substances
ENCS - Japan Existing and New Chemical Substances
ISHL - Japan Industrial Safety and Health Law
IECSC - China Inventory of Existing Chemical Substances
AICS - Australian Inventory of Chemical Substances
KECL - Korean Existing and Evaluated Chemical Substances

Carcinogenicity Rating:

Chemical Name	Percent	NTP:	IARC:	ACGIH:
Castor Oil	30-50	Not Listed	Not Listed	Not Listed
Propylene Glycol	30-50	Not Listed	Not Listed	Not Listed
Sorbitan Monooleate	5-20	Not Listed	Not Listed	Not Listed
Cyclosporine	1-9.9	Not Listed	Listed	Not Listed

SARA 313 Information

Chemical Name	Percent	SARA 313 Chemical:	CERCLA RQ/SARA EHS RQ (lbs):	SARA EHS TPQ (lbs):
Castor Oil	30-50	No	Not Applicable	Not applicable
Propylene Glycol	30-50	No	Not Applicable	Not applicable
Sorbitan Monooleate	5-20	No	Not Applicable	Not applicable
Cyclosporine	1-9.9	No	Not Applicable	Not applicable

Immediate Health: Yes
Delayed Health: Yes
Fire: No
Sudden Pressure: No
Reactivity: No

RCRA Status: Not determined.

Proposition 65 Status: Chemicals known to the State of California to cause cancer or reproductive harm listed below.

Chemical Name	Percent	Proposition 65 Listed Materials
Cyclosporine	1-9.9	Cancer

WHMIS Hazard Class: Not determined.

NFPA Rating:
 Health: 1
 Fire: 1
 Reactivity: 0

Product Name: Cyclosporine oral solution
Issued: Jun-13-2013

Notes:

1. SARA = Superfund Amendments and the Reauthorization Act.
2. CERCLA = Comprehensive Environmental Response, Compensation and Liability Act.
3. FIFRA = Federal Insecticide, Fungicide and Rodenticide Act.
4. TSCA = Toxic Substances Control Act.
5. EC = European Community.
6. WHMIS = Canadian Workplace Hazardous Materials Information System.
7. UN GHS = United Nations Globally Harmonized System for Hazard Identification.

15.2. Chemical safety assessment

Chemical safety assessment has not been conducted on the substance/product.

Section 16. Other information

Risk Phrases: R45 - May cause cancer, R60 - May impair fertility, R61 - May cause harm to the unborn child

Full text of H-Statements referred to under sections 2 and 3

H302 - Harmful if swallowed, H350 - May cause cancer if swallowed, H360FD - May damage fertility. May damage the unborn child

Document Authored By: Global Occupational Toxicology (D-03QC)

Issued: Jun-13-2013

Disclaimer:

The information and recommendations contained herein are based upon tests believed to be reliable. However, AbbVie Inc. does not guarantee their accuracy or completeness NOR SHALL ANY OF THIS INFORMATION CONSTITUTE A WARRANTY, WHETHER EXPRESSED OR IMPLIED, AS TO THE SAFETY OF THE GOODS, THE MERCHANTABILITY OF THE GOODS, OR THE FITNESS OF THE GOODS FOR A PARTICULAR PURPOSE. Adjustment to conform to actual conditions of usage may be required. AbbVie Inc. assumes no responsibility for results obtained or for incidental or consequential damages, including lost profits, arising from the use of these data. No warranty against infringement of any patent, copyright or trademark is made or implied.